Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
26
05
2020
accepted:
18
08
2020
pubmed:
4
10
2020
medline:
2
3
2021
entrez:
3
10
2020
Statut:
ppublish
Résumé
Irritable bowel syndrome (IBS) is a chronic functional bowel disorder, which follows a relapsing and remitting course. Little is known about how evolving definitions of IBS or treatment for the condition affect symptom stability. We conducted a 12-month longitudinal follow-up study of individuals who self-identified as having IBS to examine these issues. We collected demographic, gastrointestinal symptom, mood, and psychological health data at baseline, and gastrointestinal symptom data at 12 months, from adults who self-identified as having IBS, registered with 3 organizations providing services to people with IBS. We applied the Rome III and Rome IV criteria simultaneously at baseline and 12 months and subtyped participants according to predominant stool form or frequency. We examined stability of a diagnosis of IBS, and stability of IBS subtype, for the Rome IV and III criteria separately and examined the effect of commencing new therapy on fluctuation of symptoms. Of 1,375 individuals recruited at baseline, 784 (57.0%) provided data at 12 months. Of these, 452 met the Rome IV criteria for IBS at baseline, of whom 133 (29.4%) fluctuated to another functional bowel disorder at 12 months. In the remaining 319 (70.6%) who still met the Rome IV criteria for IBS, IBS subtype changed in 101 (31.7%) subjects, with IBS with mixed bowel habit (IBS-M) the least stable. Commencing a new treatment for IBS did not affect symptom stability. Among 631 who met the Rome III criteria at baseline responding at 12 months, 104 (16.5%) fluctuated to another functional bowel disorder. In the 527 (83.5%) who still met the Rome III criteria for IBS, IBS subtype fluctuated in 129 (24.5%), with IBS-M the most stable subtype. Again, commencing a new treatment for IBS did not affect symptom stability. Fluctuation between functional bowel disorders and predominant stool subtype is common in people with IBS and does not appear to be influenced solely by treatment. Rome IV IBS appears less stable than Rome III IBS.
Identifiants
pubmed: 33009062
pii: 00000434-202102000-00028
doi: 10.14309/ajg.0000000000000946
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
362-371Informations de copyright
Copyright © 2020 by The American College of Gastroenterology.
Références
Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480–91.
Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:1393–407.
Drossman DA, Thompson WG, Talley NJ. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Intl 1990;3:159–72.
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology 2020. (doi: 10.1053/j.gastro.2020.04.014 ).
doi: 10.1053/j.gastro.2020.04.014
Black CJ, Yiannakou Y, Houghton LA, et al. Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clin Gastroenterol Hepatol 2020;18:392–8.
Aziz I, Tornblom H, Palsson OS, et al. How the change in IBS criteria from Rome III to Rome IV impacts on clinical characteristics and key pathophysiological factors. Am J Gastroenterol 2018;113:1017–25.
Vork L, Weerts Z, Mujagic Z, et al. Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study. Neurogastroenterol Motil 2018;30. doi: 10.1111/nmo.13189 .
doi: 10.1111/nmo.13189
Bai T, Xia J, Jiang Y, et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey. J Gastroenterol Hepatol 2017;32:1018–25.
Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: Systematic review and network meta-analysis. Gut 2020;69:74–82.
Black CJ, Burr NE, Ford AC. Relative efficacy of tegaserod in a systematic review and network meta-analysis of licensed therapies for irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol 2020;18(5):1238–9.e1.
Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: Systematic review and network meta-analysis. Gastroenterology 2018;155:1753–63.
Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: A systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2020;5:117–31.
Halder SLS, Locke GR III, Schleck CD, et al. Natural history of functional gastrointestinal disorders: A 12-year longitudinal population-based study. Gastroenterology 2007;133:799–807.
Agreus L, Svardsudd K, Talley NJ, et al. Natural history of gastroesophageal reflux disease and functional abdominal disorders. Am J Gastroenterol 2001;96:2905–14.
Ford AC, Forman D, Bailey AG, et al. Fluctuation of gastrointestinal symptoms in the community: A 10-year longitudinal follow-up study. Aliment Pharmacol Ther 2008;28:1013–20.
Wong RK, Palsson O, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 2010;105:2228–34.
Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: Defining an alternator. Gastroenterology 2005;128:580–9.
Garrigues V, Mearin F, Badia X, et al. Change over time of bowel habit in irritable bowel syndrome: A prospective, observational, 1-year follow-up study (RITMO study). Aliment Pharmacol Ther 2007;25:323–32.
Palsson OS, Baggish JS, Turner MJ, et al. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: Implications for treatment. Am J Gastroenterol 2012;107:286–95.
Palsson OS, Baggish J, Whitehead WE. Episodic nature of symptoms in irritable bowel syndrome. Am J Gastroenterol 2014;109:1450–60.
Black CJ, Yiannakou Y, Houghton LA, et al. Anxiety-related factors associated with symptom severity in irritable bowel syndrome. Neurogastroenterol Motil 2020;32(8):e13872.
Whitehead WE; the Validation Working Team Committee in association with the Rome Questionnaire C. Development and validation of the Rome III diagnostic questionnaire. In: Drossman DA (ed). Rome III: The Functional Gastrointestinal Disorders, 3rd edn. Degnon Associates Inc: Virginia, 2006, pp 835–53.
Palsson OS, Whitehead WE, van Tilburg MA, et al. Rome IV diagnostic questionnaires and tables for investigators and clinicians. Gastroenterology 2016;150:1481–91.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395–402.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70.
Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010;32:811–20.
Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002;64:258–66.
Kamp EJ, Kane JS, Ford AC. Irritable bowel syndrome and microscopic colitis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:659–68.
Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: The prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015;42:3–11.
Irvine AJ, Chey WD, Ford AC. Screening for celiac disease in irritable bowel syndrome: An updated systematic review and meta-analysis. Am J Gastroenterol 2017;112:65–76.
Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol 2012;107:1474–82.
Gracie DJ, Guthrie EA, Hamlin PJ, et al. Bi-directionality of brain-gut interactions in patients with inflammatory bowel disease. Gastroenterology 2018;154:1635–46.e3.
Gracie DJ, Hamlin PJ, Ford AC. Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. Am J Gastroenterol 2018;113:702–12.
Nicholl BI, Halder SL, MacFarlane GJ, et al. Psychosocial risk markers for new onset irritable bowel syndrome—Results of a large prospective population-based study. Pain 2008;137:147–55.
Bolling-Sternevald E, Aro P, Ronkainen J, et al. Do gastrointestinal symptoms fluctuate in the short-term perspective? The Kalixanda study. Dig Dis 2008;26:256–63.
Agreus L, Svardsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995;109:671–80.
Ford AC, Forman D, Bailey AG, et al. Irritable bowel syndrome: A 10-year natural history of symptoms, and factors that influence consultation behavior. Am J Gastroenterol 2008;103:1229–39.
Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: Prospective evaluation using the Rome III classification. Aliment Pharmacol Ther 2012;35:350–9.
Williams RE, Black CL, Kim HY, et al. Stability of irritable bowel syndrome using a Rome II-based classification. Aliment Pharmacol Ther 2006;23:197–205.
Dorn SD, Morris CB, Hu Y, et al. Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. J Clin Gastroenterol 2009;43:214–20.
Olafsdottir LB, Gudjonsson H, Jonsdottir HH, et al. Stability of the irritable bowel syndrome and subgroups as measured by three diagnostic criteria: A 10-year follow-up study. Aliment Pharmacol Ther 2010;32:670–80.